Radius Health, Inc.
Investor Relations Department
950 Winter St
Waltham, MA 02451
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: RDUS	
Last Trade:	38.18
Trade Time:	4:00 PM ET Mar 24, 2017
Change:	0.89 (+2.387%)
Day Range	37.38 - 38.61
52-Week Range	28.00 - 59.88
Volume	990,246

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the treatment of postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA... (more)

Stock Performance

Press Releases [View all]

Mar 10, 2017
Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC

Feb 28, 2017
Radius Health to Present at Cowen and Company 37th Annual Health Care Conference

Feb 23, 2017
Radius Health Reports Fourth Quarter and Full Year 2016 Financial and Operating Results

Feb 1, 2017
Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis

Jan 31, 2017
Radius Health to Announce Fourth Quarter and Full Year 2016 Financial Results, Host Conference Call and Live Webcast on February 23, 2017

Financials [View all]

Feb 24, 2017
Annual Report (10-K)

Apr 12, 2016
Proxy Statement (DEF 14A)

Nov 3, 2016
Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)

May 5, 2016
Quarterly Report (10-Q)